Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$6.28 0.19 (2.94%) as of 4:30 Fri 5/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.19(B)
Last Volume: 4,378,853 Avg Vol: 4,460,019
52 Week Range: $4.13 - $8.81
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 14
Insider 6 Months    : 14
Insider 3/6 Months : 27.5
Guru Rank Number :  455
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 153,240 153,240 153,240 153,240
Total Buy Value $856,692 $856,692 $856,692 $856,692
Total People Bought 6 6 6 6
Total Buy Transactions 6 6 6 6
Total Shares Sold 0 0 16,866 495,199
Total Sell Value $0 $0 $135,363 $5,999,241
Total People Sold 0 0 2 9
Total Sell Transactions 0 0 2 14
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 475
  Page 12 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-11-02 4 OE $3.22 $36,916 D/D 10,856 140,883     -
   Powell Lynne Senior VP - CCO   •       •      –    2018-11-02 4 AS $8.00 $8,000 D/D (1,000) 8,605     -
   Powell Lynne Senior VP - CCO   •       •      –    2018-11-02 4 OE $3.22 $3,220 D/D 1,000 9,605     -
   Powell Lynne Senior VP - CCO   •       •      –    2018-11-01 4 AS $7.51 $11,595 D/D (1,544) 8,605     -
   Powell Lynne Senior VP - CCO   •       •      –    2018-10-19 4 AS $7.50 $750 D/D (100) 10,149     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-10-19 4 AS $7.45 $23,468 D/D (3,150) 137,383     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-10-19 4 OE $3.78 $11,907 D/D 3,150 140,533     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-10-03 4 AS $7.26 $7,802 D/D (1,072) 137,383     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-10-03 4 OE $3.22 $3,508 D/D 1,072 137,483     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-10-02 4 AS $7.19 $63,556 D/D (8,778) 137,383     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2018-10-02 4 OE $3.22 $30,085 D/D 8,778 142,911     -
   Sheridan William P Senior VP - CMO   •       •      –    2018-08-09 4 AS $7.03 $439,375 D/D (62,500) 23,213     -
   Sheridan William P Senior VP - CMO   •       •      –    2018-08-09 4 OE $1.42 $88,750 D/D 62,500 85,713     -
   Sheridan William P Senior VP - CMO   •       •      –    2018-06-01 4 AS $6.30 $265,306 D/D (42,112) 21,058     -
   Sheridan William P Senior VP - CMO   •       •      –    2018-06-01 4 OE $2.58 $108,649 D/D 42,112 63,170     -
   Hutson Nancy J Director   •       •      –    2018-06-01 4 A $6.43 $9,999 D/D 1,555 39,702     -
   Ingram Robert Alexander Director   •       •      –    2018-06-01 4 A $6.43 $18,750 D/D 2,916 21,818     -
   Stonehouse Jon P President & CEO   •       •      –    2018-05-17 4 OE $1.42 $100,006 D/D 70,427 725,519     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2018-05-15 4 D $5.91 $17,754 D/D (3,004) 95,264     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2018-05-15 4 OE $1.42 $17,750 D/D 12,500 98,268     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2018-03-06 4 D $5.18 $109,428 D/D (21,125) 108,871     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2018-03-06 4 OE $3.26 $97,800 D/D 30,000 114,773     -
   Ingram Robert Alexander Director   •       •      –    2018-03-01 4 A $4.97 $18,747 D/D 3,772 18,902     -
   Hutson Nancy J Director   •       •      –    2018-03-01 4 A $4.97 $10,000 D/D 2,012 38,147     -
   Stonehouse Jon P President & CEO   •       •      –    2018-02-28 4 D $4.97 $214,823 D/D (43,224) 655,092     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19   
  Page 12 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us